Press Releases

Emplicure receives formal notification of approved US patent for inhalation of pharmaceuticals

Emplicure AB has received issue notification from the US Patent and Trademark Office that a formal approval of the inhalation platform of pharmaceuticals will be issued on December 21, 2021.

"The United States is an important market for us. The announcement of patent approval for inhaled drugs is extremely gratifying and important, as it strengthens our conditions to develop new unique and patent-protected pharmaceutical products for inhalation", says Torbjörn W. Larsson, CEO of Emplicure.

The patent, U.S. Patent No. 11,202,871 will be valid into 2037. The information about the preliminary approval was published August 19, 2021.


Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via

For more information, please contact:

Torbjörn W. Larsson
Phone: +46 (0)70 747 65 99

Anna-Lena Nicolson
CFO, Investor Relations
Phone: +46 (0)72 33 68 68

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at


During the second quarter of 2021, Emplicure AB (publ) ("Emplicure" or "the Company") issued 9,600,000 warrants of series TO1. Each warrant entitles the holder to subscribe for one (1) new share in the Company. According to the board of directors' resolution, which was resolved pursuant to the authorization by the annual general meeting held on 13 April 2021, the subscription price for the warrants of series TO1 shall be set at 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period from and including 12 April 2022 up to and including 27 April 2022, provided however that the subscription price may not be determined to an amount less than the quota value for the Company's shares and not be determined to an amount exceeding SEK 6.23 per share. The volume-weighted average price of the Company's share during the measurement period amounted to approximately SEK 2.98 and the subscription price has thus been set at SEK 2.09. Subscription of shares with through the exercise of warrants of series TO1 shall be made during the period from and including 29 April 2022 up to and including 13 May 2022.


Under årets första kvartal har vi tagit viktiga steg i arbetet med att vidareutveckla och optimera formuleringarna i våra två huvudprojekt, Empli03 och Amp01, där vi följer den plan vi presenterade i samband med börsintroduktionen.


Our objective with Amp01 is to offer an enhanced customer experience through a significantly longer release profile of both nicotine and flavor, than what exists on the market today


Amplicon will premiere two products at the Global Forum on Nicotine, which will be held in Warsaw on 16-18 June 2022. The world's largest annual conference in the tobacco and nicotine industry attracts a large number of visitors with experts, media, consumers, and industry professionals from many countries.


The annual general meeting in Emplicure AB (publ) (the "Company") was held on Wednesday 6 April 2022 in the premises of United Spaces, Rådhuset Vaksalagatan 2, Uppsala.


As part of broadening Emplicure's project and product development, an agreement has been signed with the Department of Materials Science at Uppsala University, Sweden.

The agreement includes advanced materials science characterization of drug formulations developed by Emplicure, as well as collaboration to develop new formulations of biological drugs (biologics).


Emplicure AB (publ) today announces that a patent is set to be granted by the Australian Patent Office for inhalation of pharmaceuticals.


Emplicure AB (publ) today announces that a patent is set to be granted by the Australian Patent Office for Amplicon's nicotine inhalation technology.


Emplicure AB (publ) is set to be granted a patent by the Japan Patent Office for inhalation of pharmaceuticals.


Emplicure AB:s (publ) årsredovisning för 2021 har offentliggjorts och finns tillgänglig på Emplicures webbplats



Do you want to know more?

Contact us today.